佰仁医疗收盘上涨1.99%，滚动市盈率102.01倍，总市值148.39亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Baijun Medical, which closed at 108.0 yuan with a PE ratio of 102.01, significantly higher than the industry average of 46.15 [1][2] - Baijun Medical's total market capitalization is 14.839 billion yuan, ranking 108th in the medical device industry based on PE ratio [1][2] - As of the Q3 2024 report, Baijun Medical reported a revenue of 292 million yuan, a year-on-year increase of 13.57%, while net profit was 58.6934 million yuan, reflecting a year-on-year decrease of 16.56% [1] Group 2 - The company specializes in the research and production of animal-derived interventional medical devices, with key products including heart valve replacement and repair, congenital heart disease interventional treatment, and surgical soft tissue repair [1] - A total of 71 institutions hold shares in Baijun Medical, with a combined holding of 10.5666 million shares valued at 1.152 billion yuan [1]